Optimizing Mavenclad Prior Authorization for Gastroenterology Practices

Navigating Mavenclad Prior Authorization Within Gastroenterology Operations

Mavenclad is a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans. While not a primary treatment for core gastroenterology conditions, GI practices must manage prior authorization for all prescribed medications. Klivira's platform ensures consistent processing for high-volume drugs like Mavenclad, regardless of their primary specialty indication, by integrating with the practice's existing operational scope and EMR system.

High-Volume PA Categories Affecting Gastroenterology Practices

• IBD biologics, including TNF inhibitors (e.g., adalimumab, infliximab), integrin inhibitors (e.g., vedolizumab), and IL-12/23 inhibitors (e.g., ustekinumab, risankizumab)
• Hepatitis C direct-acting antivirals such as sofosbuvir-velpatasvir and glecaprevir-pibrentasvir
• Advanced imaging procedures like MRCP, MR enterography, and CT enterography for IBD assessment
• Endoscopic procedures with specific PA requirements, including capsule endoscopy (CPT 91110) and ERCP for certain indications
• Specialty drugs for functional GI disorders, such as eluxadoline for IBS-D or prucalopride for chronic constipation
• Non-routine colonoscopy surveillance (e.g., high-risk or post-polypectomy) on some payer plans

Essential Documentation for Prior Authorization in GI

• Diagnosis confirmation (endoscopic, imaging, histologic) for IBD biologics, adhering to ACG and AGA guidelines
• Disease severity assessment (e.g., Mayo score for UC, CDAI or Harvey-Bradshaw for Crohn's) to justify biologic use
• Documentation of prior conventional-therapy trial (e.g., 5-ASA for UC, immunomodulators for moderate-severe IBD) or prior biologic experience
• Pre-initiation screening for TB and hepatitis, required for many biologics
• Genotype, fibrosis stage (e.g., FibroSure, transient elastography), and prior-treatment history for Hepatitis C DAAs per AASLD guidelines
• Clear clinical question and prior imaging history for advanced abdominal imaging requests

Mitigating Common Prior Authorization Denials in GI

• Non-compliance with step therapy, such as requiring failure of conventional therapy or TNF biologics before other agents
• Mandatory biosimilar substitution where a brand TNF inhibitor is denied if a biosimilar should be tried first
• Insufficient documentation of disease severity (e.g., missing Mayo score or CDAI)
• Gaps in screening documentation, particularly for TB and hepatitis pre-biologic initiation
• Missing fibrosis-stage documentation or misclassification of treatment-naive vs. experienced status for Hep C DAAs
• Failure to meet payer-specific medical necessity criteria or inappropriate-use criteria for advanced imaging or capsule endoscopy

Addressing Specialty-Specific Workflow Constraints in GI

• Chronic-treatment ongoing PA burden for IBD biologics, requiring periodic re-authorization (typically every 6-12 months) with continuous documentation of disease response.
• Variability in biosimilar substitution policies across major payers, impacting brand-name biologic approvals.
• Critical importance of treatment-naive vs. treatment-experienced classification for both IBD biologics and Hep C DAAs, as misclassification drives denials.
• Cyclic nature of diagnostic-procedure PA cycles, involving initial diagnosis, surveillance, and post-treatment assessment.
• Medical-vs-pharmacy benefit split for biologic IBD drugs, where administration mode changes can shift benefit coverage for the same patient and agent.

Klivira's Platform for Comprehensive GI Prior Authorization Management

Klivira's platform is engineered to address the multifaceted prior authorization challenges faced by gastroenterology practices. We leverage intelligent automation to streamline documentation gathering, apply ACG/AGA-guideline-aware step therapy logic for IBD biologic sequencing, and manage complex workflows for Hep C DAAs, including genotype and fibrosis stage documentation. Our system automates periodic re-authorization for chronic treatments and routes medical-vs-pharmacy benefit claims, integrating seamlessly with EMRs via standards like SMART on FHIR and connecting to payer portals via X12 278 and ePA.